Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus

Trial Profile

Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTI 320 (Primary) ; Dipeptidyl peptidase 4 inhibitors; Insulins; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Boston Therapeutics; Nanomix Corporation
  • Most Recent Events

    • 26 Apr 2017 According to a Boston Therapeutics media release, recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong (CUHK) . The plans anticipate up to 10 additional institutions from the US and greater China.
    • 10 Dec 2014 The US FDA has accepted the IND for this trial, according to a Boston Therapeutics media release.
    • 06 May 2014 Status changed from unconfirmed to planning, according to a Boston Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top